Current Report Filing (8-k)
May 06 2020 - 7:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 6, 2020
AXCELLA HEALTH INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-38901
|
|
26-3321056
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
840 Memorial Drive
Cambridge, Massachusetts
|
02139
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code: (857) 320-2200
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 Par Value
|
AXLA
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events
On May 6, 2020, Axcella Health Inc. issued a press release announcing
positive top-line data from its clinical study showing multifactorial activity in adult subjects with NAFLD and hosted a conference
call and webcast to discuss such top-line data. A copy of the press release is attached hereto as Exhibit 99.1 and a copy of the
accompanying presentation used during the conference call and webcast is attached hereto as Exhibit 99.2.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AXCELLA HEALTH INC.
|
|
|
|
Date: May 6, 2020
|
By:
|
/s/ William R. Hinshaw, Jr.
|
|
|
William
R. Hinshaw, Jr.
|
|
|
Chief Executive Officer, President and Director
|
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2024 to May 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From May 2023 to May 2024